Robotic Sales Representative - Japan
PROCEPT BioRoboticsSalary not specified
- Full Time
- Mid-level (3 to 4 years)
About PROCEPT BioRobotics
PROCEPT BioRobotics develops robotic solutions specifically for treating benign prostatic hyperplasia (BPH), a condition that affects many older men by causing prostate enlargement and urinary issues. Their main product, the AquaBeam Robotic System, utilizes Aquablation therapy, which combines real-time imaging, robotics, and waterjet technology to precisely remove prostate tissue in a minimally invasive manner. This system is designed for urologists and healthcare facilities, focusing on enhancing patient outcomes and making surgical procedures more efficient. Unlike competitors, PROCEPT BioRobotics emphasizes predictable results and reduced complications, which has led to their technology being recognized in clinical guidelines. The company's goal is to improve the quality of life for patients suffering from BPH through advanced surgical solutions.
Redwood City, CaliforniaHeadquarters
2009Year Founded
$319.1MTotal Funding
IPOCompany Stage
Robotics & Automation, HealthcareIndustries
501-1,000Employees
Benefits
Health Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Parental Leave
Paid Holidays
Wellness Program
Gym Membership
Risks
Competition from Intuitive Surgical and Medtronic may impact market share.
$175 million public stock offering could lead to shareholder dilution.
Reliance on AquaBeam System makes company vulnerable to technological failures.
Differentiation
AquaBeam Robotic System offers image-guided, minimally invasive urologic surgery.
Aquablation therapy provides effective outcomes regardless of prostate size or surgeon experience.
PROCEPT has over 100 peer-reviewed publications supporting Aquablation therapy's benefits.
Upsides
Increasing adoption of robotic-assisted surgeries boosts demand for AquaBeam System.
Global urology devices market projected to grow at 6.9% CAGR until 2030.
FDA's supportive regulatory environment favors innovative medical technologies like PROCEPT's.
Funding
Total raised$319.05 M
Latest valuation$1.10 B
StageIPO
POST IPO EQUITY
9/30/2024$175
POST IPO DEBT
9/30/2022$52
IPO
8/31/2021$164
$1.10 BSERIES G
5/31/2021$85
$425.00 MSERIES F
7/31/2020$77
$385.00 MDEBT
12/31/2018$75
LATE VC
1/31/2018$118
$590.00 MSERIES D
6/30/2015$42
$210.00 MSERIES C
9/30/2013$6
$30.00 M